Page last updated: 2024-10-27
fenofibrate and Apnea, Sleep
fenofibrate has been researched along with Apnea, Sleep in 1 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Bruckert, E | 1 |
| Duchêne, E | 1 |
| Bonnefont-Rousselot, D | 1 |
| Hansel, B | 1 |
| Ansquer, JC | 1 |
| Dubois, A | 1 |
| Gaymard, B | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome[NCT00816829] | Phase 2 | 34 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to The study was prematurely terminated because of slow recruitment) |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Apneas
Total number of episodes of apneas (i.e. cessation of breathing for at least 10 seconds) from central, obstructive or mixed origin during sleep during one night after one month of treatment (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number of apneas (Median) |
|---|
| Placebo | 31.0 |
| Fenofibrate | 20.5 |
Central Apneas
Total number of central apneas (i.e. apneas with no respiratory effort present) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number of central apneas (Median) |
|---|
| Placebo | 0.0 |
| Fenofibrate | 1.0 |
Desaturations
Total number of desaturation events (i.e. defined as a decrease by 3 - 4% in oxygen saturation) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number of desaturations (Median) |
|---|
| Placebo | 171.0 |
| Fenofibrate | 130.0 |
Hypopneas
Total number of episodes of hypopneas (i.e. 50% to 80% reduction in airflow with a decrease of 3-4% in arterial oxygen saturation) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number of hypopneas (Median) |
|---|
| Placebo | 69.5 |
| Fenofibrate | 63.0 |
Index Apnea/Hypopnea
Average number of apneas and/or hypopneas per hour of sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number per hour of sleep (Median) |
|---|
| Placebo | 22.5 |
| Fenofibrate | 17.0 |
Index of Apneas
Average number of apneas per hour of sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number per hour of sleep (Median) |
|---|
| Placebo | 4.0 |
| Fenofibrate | 2.5 |
Index of Hypopneas
Average number of hypopneas per hour of sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number per hour of sleep (Median) |
|---|
| Placebo | 11.0 |
| Fenofibrate | 9.5 |
Mixed Apneas
Total number of mixed apneas (i.e. sleep apneas that have both obstructive and central component) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number of mixed apneas (Median) |
|---|
| Placebo | 0.0 |
| Fenofibrate | 1.0 |
Obstructive Apneas
Total number of obstructive apneas during sleep during one night after one month of treatment (i.e. an occlusion of the airways accompanied by ineffective respiratory efforts). (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Number of obstructive apneas (Median) |
|---|
| Placebo | 30.5 |
| Fenofibrate | 15.0 |
Sleep Time With Oxygen Saturation Below 90%
Percentage of Sleep time with oxygen saturation below 90% (measured by oximetry). Marker of consequences of apneas/hypopneas on arterial oxygenation during sleep during one night after one month of treatment. Higher percentage are worst for the patients. (NCT00816829)
Timeframe: at one month of treatment
| Intervention | Percentage of sleep time (Median) |
|---|
| Placebo | 11.5 |
| Fenofibrate | 3.5 |
Trials
1 trial available for fenofibrate and Apnea, Sleep